Announced $159.8M on 2026-01-08; Form D shows $56.9M sold as of 2026-01-14. Announced vs filed
Before you sell to, join or invest in Alveus Therapeutics, Inc.
MentionFox check on Alveus Therapeutics, Inc.: only 1 source on file so far (checked 8 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/alveus-therapeutics-inc-form-d-26000051
Check Alveus Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
Alveus Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-01-14.
Alveus Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on January 14, 2026. The filing reports $56.86M sold. Its industry group is Pharmaceuticals. It names Gregory Parekh (Director), Ivan Gergel (Director), Garrett Ingram (Director) (SEC Form D, January 14, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Alveus Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-01-14 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Alveus Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Alveus Therapeutics, Inc., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when Alveus Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Alveus Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Alveus Therapeutics, Inc. →Get the full cited report on Alveus Therapeutics, Inc.
What the filing shows about Alveus Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Alveus Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Alveus Therapeutics, Inc.'s address as 100 N. 18TH Street, Suite 1930, Philadelphia, PA 19103.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Alveus Therapeutics, Inc. See pricing
Alveus Therapeutics, Inc. is a registered filer with the SEC (CIK 2075856) and has filed since 2026-01-14. 1 filing is on record, the latest on 2026-01-14.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Alveus Therapeutics, Inc.'s Form D of 2026-01-14 names Gregory Parekh, Ivan Gergel, Garrett Ingram and 5 more as its officers, directors or promoters.
Its new offerings report $56.86M sold across 1 offering, as its own filings state.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week. The dot is this raise, $56.86M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Gregory Parekh is named as Director on the Form D that Alveus Therapeutics, Inc. filed with the SEC on 14 January 2026, one of 8 people that filing names.
Ivan Gergel is named as Director on the Form D that Alveus Therapeutics, Inc. filed with the SEC on 14 January 2026, one of 8 people that filing names.
Garrett Ingram is named as Director on the Form D that Alveus Therapeutics, Inc. filed with the SEC on 14 January 2026, one of 8 people that filing names.
Carlo de Notaristefani is named as Director on the Form D that Alveus Therapeutics, Inc. filed with the SEC on 14 January 2026, one of 8 people that filing names.
Ameet Nathwani is named as Director on the Form D that Alveus Therapeutics, Inc. filed with the SEC on 14 January 2026, one of 8 people that filing names.
Raj Kannan is named as Executive Officer and Director on the Form D that Alveus Therapeutics, Inc. filed with the SEC on 14 January 2026, one of 8 people that filing names.
Jan Van de Bossche is named as Director on the Form D that Alveus Therapeutics, Inc. filed with the SEC on 14 January 2026, one of 8 people that filing names.
Claudio Nessi is named as Director on the Form D that Alveus Therapeutics, Inc. filed with the SEC on 14 January 2026, one of 8 people that filing names.
8 people named on the filing — 1 holding an executive role and 7 as directors only.
Named as of the 2026-01-14 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Alveus Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Alveus Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alveus Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Alveus Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Alveus Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Alveus Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Philadelphia
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/alveus-therapeutics-inc-form-d-26000051